Approved for Add-on maintenance treatment of severe asthma in patients aged 6 years and older with an eosinophilic phenotype. Mepolizumab is a humanized monoclonal antibody that targets interleukin-5 (IL-5), preventing IL-5 from binding to its receptor on eosinophils. This reduces eosinophil production, maturation, and… Side effects, costs, interactions, manufacturer, and generic alternatives…
Loading full data from Know Your Drugs Institute…